Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20,563 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET-a phase I, single-arm study.
Oaknin A, Gilbert L, Tinker AV, Brown J, Mathews C, Press J, Sabatier R, O'Malley DM, Samouelian V, Boni V, Duska L, Ghamande S, Ghatage P, Kristeleit R, Leath C III, Guo W, Im E, Zildjian S, Han X, Duan T, Veneris J, Pothuri B. Oaknin A, et al. Among authors: brown j. J Immunother Cancer. 2022 Jan;10(1):e003777. doi: 10.1136/jitc-2021-003777. J Immunother Cancer. 2022. PMID: 35064011 Free PMC article. Clinical Trial.
Clinical Activity and Safety of the Anti-Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer: A Nonrandomized Phase 1 Clinical Trial.
Oaknin A, Tinker AV, Gilbert L, Samouëlian V, Mathews C, Brown J, Barretina-Ginesta MP, Moreno V, Gravina A, Abdeddaim C, Banerjee S, Guo W, Danaee H, Im E, Sabatier R. Oaknin A, et al. Among authors: brown j. JAMA Oncol. 2020 Nov 1;6(11):1766-1772. doi: 10.1001/jamaoncol.2020.4515. JAMA Oncol. 2020. PMID: 33001143 Free PMC article. Clinical Trial.
Clinical activity and safety of the anti-PD-1 monoclonal antibody dostarlimab for patients with recurrent or advanced dMMR endometrial cancer.
Oaknin A, Tinker AV, Gilbert L, Samouëlian V, Mathews C, Brown J, Barretina-Ginesta MP, Moreno V, Gravina A, Abdeddaim C, Banerjee S, Guo W, Danaee H, Im E, Sabatier R. Oaknin A, et al. Among authors: brown j. Future Oncol. 2021 Oct 1;17(29):3781-3785. doi: 10.2217/fon-2021-0598. Epub 2021 Aug 24. Future Oncol. 2021. PMID: 34427115 Free article.
Patient-reported outcomes in the GARNET trial in patients with advanced or recurrent mismatch repair-deficient/microsatellite instability-high endometrial cancer treated with dostarlimab.
Kristeleit R, Mathews C, Redondo A, Boklage S, Hanlon J, Im E, Brown J. Kristeleit R, et al. Among authors: brown j. Int J Gynecol Cancer. 2022 Aug 16;32(10):1250-7. doi: 10.1136/ijgc-2022-003492. Online ahead of print. Int J Gynecol Cancer. 2022. PMID: 35973737 Free PMC article.
When to Operate, Hesitate and Reintegrate: Society of Gynecologic Oncology Surgical Considerations during the COVID-19 Pandemic.
Fader AN, Huh WK, Kesterson J, Pothuri B, Wethington S, Wright JD, Bakkum-Gamez JN, Soliman PT, Sinno AK, Leitao M, Martino MA, Karam A, Rossi E, Brown J, Blank S, Burke W, Goff B, Yamada SD, Uppal S, Dowdy SC. Fader AN, et al. Among authors: brown j. Gynecol Oncol. 2020 Aug;158(2):236-243. doi: 10.1016/j.ygyno.2020.06.001. Epub 2020 Jun 6. Gynecol Oncol. 2020. PMID: 32532460 Free PMC article. Review.
Molecular profiles of endometrial cancer tumors among Black patients.
Wilhite AM, Baca Y, Xiu J, Paladugu R, ElNaggar AC, Brown J, Winer IS, Morris R, Erickson BK, Olawaiye AB, Powell M, Korn WM, Rocconi RP, Khabele D, Jones NL. Wilhite AM, et al. Among authors: brown j. Gynecol Oncol. 2022 Jul;166(1):108-116. doi: 10.1016/j.ygyno.2022.04.014. Epub 2022 Apr 28. Gynecol Oncol. 2022. PMID: 35490034
20,563 results
You have reached the last available page of results. Please see the User Guide for more information.